One of the most common questions we receive is: 'Can I use my own stem cells instead?' It's a reasonable question. The short answer is: technically yes, practically no — and here's why.
The Difference: Autologous vs. Allogeneic
'Autologous' therapy uses cells harvested from the patient's own body — typically from bone marrow or adipose tissue. 'Allogeneic' therapy uses cells from a donor. At True Regen Medical, all protocols use allogeneic MSCs derived from umbilical cord tissue (specifically Wharton's jelly). Our lab partner Regen Cord manufactures these cells.
Why Not Your Own Cells?
Age and Disease Compromise Cell Quality
Your own MSCs are subject to the same aging processes and inflammatory environment as your other cells. A 60-year-old with chronic autoimmune disease has MSCs that are, in many measurable ways, less potent than those from a healthy newborn donor. Research consistently shows that autologous MSCs from older or chronically ill patients have reduced proliferative capacity, shorter telomeres, and diminished paracrine signaling compared to allogeneic MSCs from umbilical cord tissue.
The Practical Problem: Time
Harvesting your own MSCs requires an invasive procedure — bone marrow aspiration or liposuction of adipose tissue. Then the cells need to be sent to a lab, expanded to therapeutic quantities (300 million+ cells per infusion), quality tested, and frozen for transport. This process takes 4–8 weeks minimum, and often longer.
This means: one visit to harvest, return home, wait weeks, then fly back for treatment. Or remain in Colombia for over a month. For most patients traveling internationally for medical care, this is not practical.
No Immune Advantage in Practice
The theoretical advantage of autologous therapy is zero immune rejection risk. In practice, allogeneic MSCs from Wharton's jelly have an exceptionally low immunogenicity profile — they express very low levels of MHC Class II antigens (the markers that trigger T-cell rejection). In decades of clinical use, immune rejection of well-characterized allogeneic MSCs is exceedingly rare. The 'use your own cells to be safe' instinct is understandable but is not supported by the actual risk data for this cell type.
The Certificate of Analysis
Every batch of MSCs we use comes with a Certificate of Analysis from Regen Cord. This document certifies: cell count, viability (typically >95%), sterility, mycoplasma-free status, and potency markers. You receive this document before your infusion — not after. This level of quality documentation is generally not available with autologous cell preparations.
The Bottom Line
Allogeneic umbilical cord MSCs are the current standard in high-quality MSC therapy for a reason: they're younger, more potent, immediately available, rigorously tested, and have decades of safety data. If autologous therapy is important to you for personal or medical reasons, raise it on your evaluation call — we'll give you an honest, personalized assessment of whether the benefit/burden ratio makes sense in your case.